Mukherjee B, Alam M S, Krishnakumar S. A rare case of bilateral orbital Castleman disease. Orbit, 2014, 33(4): 314-317. DOI: 10.3109/01676830.2014.904381.
Kurokawa T, Suzuki S, Kawaguchi K, et al. Castleman disease presenting with ophthalmic signs and symptoms. Am J Ophthalmol, 1999, 128(1): 114-116. DOI: 10.1016/s0002- 9394(99)00027-6.
[9]
Venizelos I, Papathomas T G, Papathanasiou M, et al. Orbital Involvement in Castleman Disease.Surv Ophthalmol, 2010, 55(3): 247-255. DOI: 10.1016/j.survophthal.2009.09.003.
[10]
Sato Y , Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol, 2009, 22(4): 589- 599. DOI: 10.1038/modpathol.2009.17.
Sato Y, Kojima M , Takata K, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol, 2010, 63(12): 1084-1089. DOI: 10.1136/jcp.2010.082958.
[14]
Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg, 2012, 255(4): 677-684. DOI: 10.1097/SLA.0b013e318249dcdc.
[15]
Van Rhee F, Casper C, Voorhees PM, et al. A phase 2, openlabel, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget, 2015, 6(30): 30408- 30419. DOI: 10.18632/oncotarget.4655.